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Cerebral malaria is a severe complication of human malaria and may lead to death of 
Plasmodium falciparum-infected individuals. Cerebral malaria is associated with seques-
tration of parasitized red blood cells within the cerebral microvasculature resulting in 
damage of the blood–brain barrier and brain pathology. Although CD8+ T cells have 
been implicated in the development of murine experimental cerebral malaria (ECM), 
several other studies have shown that CD8+ T cells confer protection against blood-
stage infections. Since the role of host deubiquitinating enzymes (DUBs) in malaria is yet 
unknown, we investigated how the DUB cylindromatosis (CYLD), an important inhibitor 
of several cellular signaling pathways, influences the outcome of ECM. Upon infection 
with Plasmodium berghei ANKA (PbA) sporozoites or PbA-infected red blood cells, at 
least 90% of Cyld−/− mice survived the infection, whereas all congenic C57BL/6 mice 
displayed signatures of ECM, impaired parasite control, and disruption of the blood–
brain barrier integrity. Cyld deficiency prevented brain pathology, including hemorrhagic 
lesions, enhanced activation of astrocytes and microglia, infiltration of CD8+ T cells, and 
apoptosis of endothelial cells. Furthermore, PbA-specific CD8+ T cell responses were 
augmented in the blood of Cyld−/− mice with increased production of interferon-γ and 
granzyme B and elevated activation of protein kinase C-θ and nuclear factor “kappa 
light-chain enhancer” of activated B cells. Importantly, accumulation of CD8+ T cells in 
the brain of Cyld−/− mice was significantly reduced compared to C57BL/6 mice. Bone 
marrow chimera experiments showed that the absence of ECM signatures in infected 
Cyld−/− mice could be attributed to hematopoietic and radioresistant parenchymal cells, 
most likely endothelial cells that did not undergo apoptosis. Together, we were able to 
show that host deubiqutinating enzymes play an important role in ECM and that CYLD 
promotes ECM supporting it as a potential therapeutic target for adjunct therapy to 
prevent cerebral complications of severe malaria.
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inTrODUcTiOn
Proteolytic removal of ubiquitin and ubiquitin-like modifica-
tions on key target proteins in signaling pathways permits 
rapid responses to environmental cues (1). A central regulatory 
pathway in innate and adaptive immunity is controlled by the 
nuclear factor “kappa light-chain enhancer” of activated B cells 
(NF-κB), which is essential for inflammatory responses and 
pathogen defense (2). For termination of inflammation, NF-κB 
needs to be inactivated through the activity of deubiquitinating 
enzymes (DUBs) such as A20 and CYLD (3). Cylindromatosis 
(turban tumor syndrome), also called CYLD, was originally 
identified as tumor suppressor gene, a mutation of which causes 
tumors of the hair follicles (cylindromas) (4, 5). CYLD is a DUB 
and negatively regulates activation of NF-κB, mitogen-activated 
protein kinases, and type I interferon (IFN) production by 
specifically cleaving lysine 63-linked polyubiquitin chains from 
several signaling molecules (6), including transforming growth 
factor beta-activated kinase 1, tumor necrosis factor (TNF) 
receptor-associated factors (TRAF) 2, TRAF6, B cell lymphoma 
3, NF-κB essential modulator, retinoic acid-inducible gene 1, 
receptor-interacting serine/threonine kinase 2 (RIPK2), and 
signal transducer and activator of transcription 3 (STAT3) 
(7–12), thereby regulating non-degradative functions like 
protein trafficking, protein–protein interaction, and signal 
transduction.
Very few studies have addressed the role of CYLD in infec-
tious diseases. Cyld−/− mice infected with Haemophilus influenzae 
and Escherichia coli develop hyperinflammation due to a strong 
activation of the NF-κB signaling pathway (13, 14). On the con-
trary, CYLD deficiency protects mice from pneumolysin-induced 
acute lung injury and lethality (15). Previously, we have shown 
that CYLD inhibits IL-6 production by macrophages, which in 
turn induces STAT3-dependent protective fibrin production by 
hepatocytes in listeriosis (11). In addition, we could also show 
that CYLD impaired antilisterial immune responses in mac-
rophages by deubiquitinating the kinase RIPK2 (12). However, 
how CYLD influences the course of parasitic infections remains 
entirely unknown.
Cerebral malaria is one of the most severe complications 
caused by infection with Plasmodium falciparum with fatality 
rates up to 25% (16). Brain pathology includes cerebral bleed-
ing, brain edema, seizures, coma and, ultimately, death (17, 18). 
Experimental cerebral malaria (ECM), the rodent disease model 
of human cerebral malaria, is a widely used surrogate model to 
study the pathogenesis of cerebral malaria (19–21). A hallmark 
of cerebral malaria is the sequestration of Plasmodium-infected 
red blood cells on the brain vascular endothelium (22–24). 
Other characteristic features include activation of endothelial 
cells (25), production of proinflammatory cytokines and 
chemokines (26, 27), and disruption of the blood–brain barrier 
integrity (28). CD8+ T cells are known to play an important role 
in the pathology of ECM (29–31). CD8+ T cells mediate the 
disruption of the blood–brain barrier by fostering leukocyte 
accumulation (32) and by inducing apoptosis of endothelial 
cells through granzyme B and perforin-mediated cytotoxicity 
(29, 30). However, recent reports have suggested a protective 
role of CD8+ T cells against blood-stage malaria. CD8+ T cells 
eliminate Plasmodium-infected red blood cells and also modu-
late the immune response through production of cytokines 
(33–35).
Currently, the functional relevance of DUBs in human and 
ECM is completely unknown. In this study, we describe that Cyld 
expression in the hematopoietic and parenchymal cells lethally 
aggravated ECM, whereas Cyld-deficient mice were protected. 
Furthermore, we uncovered a dual function of CYLD in the 
pathogenesis of ECM: (i) CYLD impaired activation of PKC-θ 
and NF-κB in CD8+ T cells and (ii) CYLD promoted apoptosis 
of endothelial cells, thereby augmenting brain pathology and 
preventing survival during ECM.
resUlTs
cYlD is essential for the Development of 
Plasmodium berghei anKa (Pba)-induced 
ecM
To study the function of CYLD in ECM, WT and Cyld−/− mice 
were infected intravenously (i.v.) with 20,000 PbA sporozoites. 
WT mice developed signature ECM symptoms, such as ataxia, 
loss of grip strength, and progressive paralysis, within 7  days 
postinfection (p.i.) (Figure 1A). In contrast, 90% of the infected 
Cyld−/− mice survived without showing any symptoms of ECM. 
Similarly, on intraperitoneal (i.p.) infection with 106 PbA-infected 
red blood cells, all Cyld−/− mice were protected from PbA blood 
stage-induced ECM (Figure 1B). The brains of PbA-infected WT 
mice displayed extensive blood–brain barrier damage as shown 
by Evans blue distribution, while the brains of infected Cyld−/− 
mice showed no vascular leakage (Figures  1C,D), illustrating 
that CYLD is essential for the development ECM. A secondary 
lethal outcome of PbA infection in WT mice is anemia around 
day 20 after infection (Figures 1A,B). In contrast to infected WT 
mice that did not survive beyond day 20, severe complications 
from parasite-induced anemia were not observed in infected 
Cyld−/− mice.
On infection with blood-stage PbA, parasitemia was detectable 
in WT and Cyld−/− mice at day 3 p.i., and parasitemia progres-
sively increased in both mouse strains (Figure 1E). However, the 
parasite burden was significantly reduced in Cyld−/− mice at day 
7 p.i. Similarly, on sporozoite infection, parasitemia increased 
in both strains of mice from day 3 p.i. onward (Figure 1F). This 
finding suggests that CYLD had no major impact on preeryth-
rocytic parasite replication in the liver. As was seen in infections 
by blood transfusion, sporozoite-induced infections resulted in 
a significantly reduced number of parasites in Cyld−/− mice at 
day 7 p.i.
Presence of cYlD leads to  
ecM-associated Brain Pathology
To further study the effect of CYLD in ECM-associated brain 
pathology, a detailed histopathological analysis was performed 
(Figure 2). At day 7 p.i., WT mice showed severe brain hemor-
rhage, which was absent in Cyld−/− mice (Figure 2A). WT, but not 
FigUre 1 | Cyld−/− mice are protected from Plasmodium berghei anKa (Pba)-induced experimental cerebral malaria. (a) C57BL/6 Cyld−/− and WT 
(n = 10 each) mice were intravenously (i.v.) infected with 20,000 PbA sporozoites, and survival rates were monitored daily up to day 28 postinfection (p.i.). Data 
represent one of two independent experiments. (B) C57BL/6 Cyld−/− and WT (n = 10 each) mice were intraperitoneally infected with 1 × 106 PbA-infected red blood 
cells, and the survival was monitored daily up to day 28 p.i. Data represent one of two independent experiments, p < 0.05 (log-rank test). (c,D) At day 7 p.i., Evans 
Blue was injected i.v. in mice infected with PbA sporozoites (c) and PbA-parasitized red blood cells (D). The mice were euthanized 1 h later and perfused with 
saline, and the isolated brains were photographed. Representative images from three independent experiments are shown. (e,F) The percentage of parasitized 
erythrocytes in the peripheral blood was enumerated daily from Giemsa-stained thin blood smears after infection with PbA sporozoites (e) and PbA-infected red 
blood cells (F), p < 0.05 (two-tailed Student’s t-test).
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Cyld−/−, mice developed widespread neuroinflammation charac-
terized by astrogliosis with increased expression of glial fibrillary 
acidic protein (GFAP) in activated astrocytes (Figure  2B) and 
ionized calcium-binding adapter molecule 1 (Iba1)+-ramified 
microglia (Figure 2C).
Furthermore, MHC class I staining on microglial cells, some 
of which were tightly associated with cerebral microvessels, 
was strongly upregulated in the brains of infected WT mice 
(Figure 2D). This was paralleled by focal intracerebral infiltration 
of CD8+ T cells in WT mice (Figure 2E). Interestingly, CD31/
PECAM-1+ staining intensity on endothelial cells was consider-
ably stronger in WT compared to Cyld−/− mice (Figure 2F). In 
addition, CD31+ WT endothelial cells were frequently positive 
for cleaved caspase-3, an apoptosis-inducing effector caspase 
(Figures 2G,H).
Taken together, our data show that the presence of CYLD pro-
motes brain pathology with increased neuroinflammation and 
hemorrhage as well as endothelial cell activation and apoptosis.
FigUre 2 | cylindromatosis (cYlD) augments brain pathology in experimental cerebral malaria. Histopathology of WT and Cyld−/− mice at day 7 
postinfection (p.i.). (a) hematoxylin and eosin staining showing numerous hemorrhagic lesions scattered throughout the brain of WT mice at day 7 p.i. Pronounced 
activation of astrocytes (B) and microglia (c) in the brain of a WT mouse as shown by glial fibrillary acidic protein and ionized calcium–binding adaptor molecule 1 
staining, respectively. (D) Strong immunostaining of MHC class I molecules on microglial cells in a brain of WT mouse. (e) Accumulation of CD8+ T cells in the brain 
of a WT mouse at day 7 p.i. (F) CD31 staining shows a prominent staining pattern on endothelial cells in the brain of a WT mouse. (g) Apoptosis of endothelial cells 
is visualized in the brain of a WT mouse by active caspase-3 staining in a vessel wall. (h) Double immunofluorescence shows co-localization of CD31+ endothelial 
cells (green) with active caspase 3 (red) in the brain of a WT mouse at day 7 p.i., while this is not found in a Cyld−/− mouse. Representative staining results of three 
independent experiments are displayed.
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FigUre 3 | reduced proinflammatory cytokine expression in the brain of Cyld−/− mice. Quantitative reverse transcription polymerase chain reaction analysis 
of intracerebral cytokines interferon-γ, perforin, granzyme B, tumor necrosis factor, interleukin-6, lymphotoxin-α, and chemokines CXCL-9 and CXCL-10 mRNA 
expression in WT and Cyld−/− mice. Data show the increase of the respective mRNA expression of Plasmodium berghei ANKA-infected over uninfected mice of the 
same mouse strain. Data represent the mean (±SD) of six mice, *p < 0.05 (two-tailed Student’s t-test). Data from two independent experiments are shown.
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cYlD augments cytokine Production in 
the Brain of Pba-infected Mice
Since cytokines and chemokines regulate the immunopathologi-
cal processes leading to ECM, we next determined cytokine and 
chemokine levels in the brain and peripheral blood of PbA-
infected mice. At day 7 p.i., quantitative reverse transcription 
polymerase chain reaction (RT-PCR) revealed that steady-state 
mRNA levels of IFN-γ, perforin, and lymphotoxin (LT)-α were 
significantly reduced in the brain of Cyld−/− mice, while levels 
of granzyme B, TNF, IL-6, CXCL-9, and CXCL-10 levels were 
comparable between the two mouse strains (Figure 3). This find-
ing indicates that local expression of proinflammatory cytokines 
is significantly reduced in the absence of CYLD. This contrasts 
with systemic serum cytokine concentrations, since IFN-γ was 
increased in serum of Cyld−/− mice as compared to WT mice, 
whereas the levels of IL-2, IL-4, IL-6, IL-10, IL-17, and TNF levels 
did not differ significantly between the two mouse strains at day 
7 p.i. (Figure S1 in Supplementary Material).
cYlD reduces Parasite-specific cD8+ 
T cell responses in Peripheral Blood
Since the parasitemia in Cyld−/− mice was reduced and CD8+ 
T cells typically play an important role in the control of intracel-
lular pathogens, we determined the influence of CYLD on the 
CD8+ T cell numbers in the blood during ECM. Before infection, 
WT and Cyld−/− mice harbored equally low numbers of CD8+ 
T cells (Figure 4A). On infection with PbA-infected red blood 
cells, both the percentage and the total number of CD8+ T cells 
(Figures  4A,B), as well as PbA-specific H2-Db SQLLNAKYL 
pentamer+ CD44+ CD8+ T cells, were significantly increased in 
Cyld−/− mice at day 7 p.i. (Figures 4C,E).
In addition, absolute (Figure  4D) and relative (Figure  4F, 
Figure S2A in Supplementary Material) numbers of PbA antigen-
specific IFN-γ- and granzyme B-producing CD8+ T cells, that 
recognize the blood-stage PbA epitope GAP-50 (36), were also 
significantly increased in the blood of Cyld−/− mice. Similar results 
were obtained upon i.p. infection with PbA-infected red blood 
cells (Figures S2B,C in Supplementary Material). These findings 
indicate an association of the magnitude of antigen-specific CD8+ 
T cells with parasite clearance.
cYlD reduces activation of PKc-θ and 
impairs nF-κB activation in cD8+ T cells
Since the stimulation of the T cell receptor induces NF-κB 
activation via the PKC-θ pathway (37), we performed an ex vivo 
analysis of levels of PKC-θ and p65, a constituent of the NF-κB 
complex, by flow cytometry in CD8+ T cells (Figure  5). PbA 
infection induced increased phosphorylation of both PKC-θ and 
FigUre 4 | augmented cD8+ T cell responses increase in the blood of Cyld−/− mice. (a,B) Absolute (a) and representative relative (B) numbers of CD3+ 
CD8+ T cells of uninfected (day 0) and Plasmodium berghei ANKA (PbA) blood stage-infected mice (day 7) were determined by flow cytometry in the blood of WT 
and Cyld−/− mice (n = 6 each), *p < 0.05 (two-tailed Student’s t-test). (c–F) Absolute (c) and representative relative numbers (e) of H2-Db SQLLNAKYL pentamer+ 
CD44+ CD8+ T cells. Absolute (D) and representative relative numbers (F) of interferon-γ-producing CD8+ T cells from uninfected (day 0) and PbA-infected mice at 
day 7 postinfection after ex vivo restimulation with GAP-50 peptide (n = 6 each), *p < 0.05 (two-tailed Student’s t-test). Data from one of three independent 
experiments are shown.
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FigUre 5 | activation of PKc-θ and nuclear factor “kappa light-chain enhancer” of activated B cells is augmented in cyld−/− cD8+ T cells. (a) The 
gating strategy used to identify CD45+ CD3+ CD8+ T cells is illustrated. (B,D) Histogram overlays show p-PKC-θ (B) and p-p65 (D) expression in CD3+ CD8+ T cells 
of uninfected (day 0) and infected (day 7) WT and Cyld−/− mice. The intracellular mean fluorescence intensity of PKC-θ (c) and p-p65 (e) is shown for WT and 
Cyld−/− mice at the indicated time points. Specific staining for WT mice is shown in light gray and for Cyld−/− mice in dark gray. Data show the mean (±SD) of six 
mice from one of two experiments.
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p65 in CD45+ CD3+ CD8α+ T cells from WT and Cyld−/− mice 
(Figures 5A–E). However, phosphorylation of both PKC-θ and 
p65 was significantly more pronounced in Cyld−/− mice. Thus, 
CYLD, which is known to interact with PKC-θ (38), impaired 
the activation of PKC-θ and NF-κB in CD8+ T cells.
cYlD augments cD8+ T cell response  
in the Brain
Since pathogenic CD8+ T cells mediate end-stage immune pathol-
ogy in ECM [reviewed in Ref. (39)], the intracerebral CD8+ T cell 
response of WT and Cyld−/− mice were analyzed in detail by flow 
cytometry (Figure 6). Uninfected WT and Cyld−/− mice harbored 
very low numbers of CD8+ T cells in the brain (Figure 6A). Upon 
infection, both the percentage and the total number of CD8+  
T cells (Figures  6A,B), as well as PbA-specific H2-Db 
SQLLNAKYL pentamer+ CD44+ CD8+ T cells (Figure  6C), 
were significantly increased in the brains of WT mice at day 7 
p.i. Numbers of PbA GAP-50-specific CD8+ T cells producing 
IFN-γ, TNF, and granzyme B were reduced in the brains of 
Cyld−/− mice (Figure 6D). However, only differences for IFN-γ 
were statistically significant upon infection with blood-stage 
PbA (Figures 6D,E). We could independently confirm these data 
by sporozoite infection (Figure S3 in Supplementary Material). 
Together, our findings corroborate the notion that antigen-
specific CD8+ T cells might contribute to ECM pathology.
cYlD impairs Parasite clearance  
by cD8+ T cells
To determine whether the improved parasite control of Cyld−/− 
mice is mediated by CYLD-deficient CD8+ T cells, we depleted 
CD8+ T cells in WT and Cyld−/− mice before infection (Figure S4 
in Supplementary Material) and assessed the survival, vascular 
leakage, and parasite load. Infected WT and Cyld−/− mice with 
CD8+ T cell depletion showed no vascular leakage (Figure 7A) 
FigUre 6 | Diminished cD8+ T cell response in the brain of Cyld−/− mice. (a,B) Absolute (a) and representative relative (B) numbers of CD3+ CD8+ T cells of 
uninfected (day 0) and Plasmodium berghei ANKA (PbA)-blood stage-infected mice (day 7) were determined by flow cytometry in the brains of WT and Cyld−/− mice 
(n = 6 each). (c) Absolute numbers of H2-Db SQLLNAKYL pentamer+ CD44+ CD8+ T cells. (D) Absolute numbers of interferon (IFN)-γ, tumor necrosis factor, and 
granzyme B-producing CD8+ T cells of uninfected (day 0) and PbA-infected mice (day 7) after ex vivo restimulation with GAP-50 peptide. (e) Representative relative 
numbers of IFN-γ-producing CD8+ T cells from (D), *p < 0.05 (two-tailed Student’s t-test). (a–e) Data from one of three independent experiments are shown.
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and survived the infection (Figure 7B), but harbored increased 
parasite loads compared to the WT and Cyld−/− mice receiving 
control antibody (Figure 7C). However, the parasite load in the 
CD8+ T cell-depleted Cyld−/− mice was always lower compared 
to CD8+ T cell-depleted WT mice, indicating that in addition to 
the contribution of CD8+ T cells the enhanced parasite control 
in the Cyld−/− mice is also mediated by other cell types, likely 
Cyld−/− macrophages and granulocytes.
cYlD augments cytokine Production but 
impairs chemokine receptor expression 
by cD8+ T cells
Although the parasite-specific CD8+ T cell response was 
enhanced in the peripheral blood of Cyld−/− mice, these mice 
harbored reduced numbers of pathogen-specific CD8+ T  cells 
in the brain. Since chemokine receptors are essential for migra-
tion of CD8+ T cells, we checked for the cell numbers, cytokine 
production and the chemokine receptor expression of parasite-
specific CD8+ T cells in the spleen. Upon infection with blood-
stage PbA, the total number of parasite-specific CD8+ T  cells 
were strongly increased in the spleen of Cyld−/− mice at day 7 
p.i. (Figure 8A).
In addition, absolute (Figures  8B,D) and relative 
(Figures  8C,E) numbers of PbA antigen-specific IFN-γ- and 
granzyme B-producing GAP-50-specific CD8+ T cells were 
significantly increased in the spleen of infected Cyld−/− mice. In 
marked contrast, expression of the chemokine receptor CXCR3 
was significantly reduced in Cyld−/− CD8+ T cells (Figures 8F,G). 
A small, albeit non-significant, reduction in Cyld−/− CD8+ T cells 
FigUre 7 | Depletion of cD8+ T cells rescues mice from experimental cerebral malaria. C57BL/6 Cyld−/− and WT (n = 6 each) mice were either treated with 
anti-CD8 antibody or rat IgG starting 3 days before intraperitoneal (i.p.) infection and i.p. 1 × 106 Plasmodium berghei ANKA (PbA)-infected red blood cells. (a) At 
day 7 postinfection (p.i.), Evans Blue was injected intravenously in mice. The mice were euthanized 1 h later and perfused with saline, and the isolated brains were 
photographed. Representative images from two independent experiments are shown. (B) Survival was monitored daily until day 14 p.i. (c) The percentage of 
parasitized erythrocytes in the peripheral blood was enumerated daily from Giemsa-stained thin blood smears. (a–c) *p < 0.05 (two-tailed Student’s t-test) 
Representative data from two independent experiments are shown.
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was also detected for CCR5 (Figures S5A,B in Supplementary 
Material) and CCR1 (Figures S5C,D in Supplementary Material). 
Since CXCR3 plays an important role in migration of CD8+ 
T cells to the brain (40), the reduced accumulation of CD8+ T in 
the brain of Cyld−/− mice may be attributed to reduced levels of 
CXCR3.
cD4+ T cell responses are augmented  
in the Blood but reduced in the Brain  
of Cyld−/− Mice
Since CD4+ T cells also play an important role in the control of 
blood-stage malaria, we determined the influence of CYLD on the 
CD4+ T cell numbers in the blood and brain during ECM. Before 
infection, WT and Cyld−/− mice harbored equal numbers of CD4+ 
T cells in the blood (Figure 9A) and brain (Figure 9B). Upon 
infection with PbA-infected red blood cells, the total number of 
CD4+ T cells increased in the blood and brain of both mouse 
strains. However, the numbers of CD4+ T cells were strongly 
increased in the blood (Figure 9A), but markedly reduced in the 
brain of Cyld−/− mice (Figure 9B).
In addition, absolute (Figure  9C) and relative (Figure  9E) 
numbers of PbA antigen-specific IFN-γ-producing CD4+ T cells 
were significantly increased in the blood of Cyld−/− mice, but 
lower in the brain of Cyld−/− mice (Figures 9D,F). These findings 
indicate that similar to CD8+ T cells, the CD4+ T cell response to 
PbA is also regulated by CYLD.
absence of ecM in infected Cyld−/− Mice 
is Mediated by Both hematopoietic and 
Parenchymal cells
To validate whether the lethal course of cerebral malaria in 
the WT mice was caused by hematopoietic or parenchymal 
cells, reciprocal bone marrow chimera of WT and Cyld−/− mice 
were generated (Figure  10). Eight weeks after bone marrow 
transplantation, mice were infected with PbA-parasitized red 
blood cells. Seventy-five percent of WT mice reconstituted with 
Cyld−/− bone marrow did not develop clinical signs of ECM, 
whereas 50% of Cyld−/− mice reconstituted with WT bone 
marrow did show signature symptoms of ECM (Figure 10A). 
In accordance with non-irradiated mice, all Cyld−/− mice 
reconstituted with Cyld−/− bone marrow remained healthy, 
whereas all WT mice reconstituted with WT bone marrow 
developed signature ECM symptoms. Thus, the clinical conse-
quences of infection appear to depend on both Cyld-expressing 
hematopoietic and parenchymal cells from donor and recipient 
animals, respectively.
Furthermore, WT mice reconstituted with Cyld−/− bone 
marrow harbored low parasite numbers in the blood. Lower 
parasitemia was comparable with the Cyld−/− mice reconstituted 
with Cyld−/− bone marrow (Figure 10B). In contrast, Cyld−/− mice 
reconstituted with WT bone marrow harbored significantly 
higher parasite burden, which in turn was comparable to WT 
mice reconstituted with WT bone marrow (Figure 10B). These 
FigUre 8 | enhanced cD8+ T cell responses but reduced cXcr3 expression by cD8+ T cells in the spleen of Cyld−/− mice. (a) Absolute numbers of 
SQLLNAKYL pentamer+ CD44+ CD8+ T cells of uninfected mice (day 0) and mice infected with Plasmodium berghei ANKA (PbA)-blood stage parasites (1 × 106 
intraperitoneally) were determined by flow cytometry in the brains of WT and Cyld−/− mice at day 7 postinfection (p.i.) (n = 6 each). (B–e) Absolute (B) and relative 
(c) numbers of interferon-γ-producing CD8+ T cells and absolute (D) and relative (e) numbers granzyme B-producing CD8+ T cells from uninfected mice (day 0) and 
PbA-infected mice at day 7 p.i. after ex vivo restimulation with GAP-50 peptide (n = 6 each), *p < 0.05 (two-tailed Student’s t-test). Data from one of three 
independent experiments are shown. (F) Histogram overlays show data for CXCR3 expression in CD3+ CD8+ T cells of uninfected (day 0) and infected (day 7) WT 
and Cyld−/− mice. (g) The intracellular mean fluorescence intensity of CXCR3 is shown for WT and Cyld−/− mice at the indicated time points. (a,c,e) ND = non-
detectable. (a,c,e) Data show the mean (±SD) of six mice from one of two experiments.
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data indicate an exclusive contribution of hematopoietic cells in 
the parasite control during infection.
To further analyze whether transplantation of Cyld−/− bone 
marrow cells into WT mice improved parasite-specific T cell 
responses in WT mice, the number of GAP-50-specific CD8+ 
T  cells was determined. In blood, the total number of CD8+ 
T cells (Figure 10C) as well as IFN-γ- and granzyme B-producing 
GAP-50-specific CD8+ T cells (Figure 10D) was increased in WT 
FigUre 9 | cD4+ T cell responses increase in the blood and decrease in the brain of Cyld−/− mice. (a,B) Total numbers of CD3+ CD4+ T cells in blood (a) 
and brain (B) of uninfected (day 0) and Plasmodium berghei ANKA (PbA)-infected (day 7) WT and Cyld−/− mice were determined by flow cytometry (n = 6 each), 
*p < 0.05 (two-tailed Student’s t-test) (c–F) Absolute (c) and representative relative (e) numbers of interferon (IFN)-γ-producing CD4+ T cells in blood and absolute 
(D) and representative relative (F) numbers of IFN-γ-producing CD4+ T cells in the brain from uninfected (day 0) and PbA-infected mice (day 7) after ex vivo 
restimulation with anti-CD3/CD28 (n = 6 each), *p < 0.05 (two-tailed Student’s t-test). Data from one of three independent experiments are shown.
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mice receiving Cyld−/− bone marrow, suggesting an important 
contribution of CYLD in the hematopoietic cell population from 
the donor mice in modulating systemic CD8+ T cell responses.
In the brains of bone marrow chimeric mice, significantly 
reduced numbers of the total CD8+ T cells (Figure  10E), as 
well as IFN-γ and granzyme B-producing GAP-50-specific 
FigUre 10 | Deletion of Cyld in both the hematopoietic and the parenchymal compartment contributes to protection from experimental cerebral 
malaria. (a–F) A total of 10 × 106 Bone marrow cells isolated from WT and Cyld−/− mice, respectively, and 10 × 106 cells were adoptively transferred into sublethally 
irradiated (one dose of 12 Gy) WT and Cyld−/− mice as indicated. Eight weeks after bone marrow transfer, chimeras were infected with 1 × 106 Plasmodium berghei 
ANKA (PbA) parasitized red blood cells. (a) The survival of mice was monitored until day 14 postinfection. (B) The percentage of parasitized erythrocytes in the 
peripheral blood was enumerated daily from Giemsa-stained thin blood smears. Data represent the mean ± SD (n = 4 each). (c,e) Absolute numbers of total CD45+ 
leukocytes in the blood (c) and brain (e) of PbA-infected mice (day 7). (D,F) Absolute number of interferon-γ- and granzyme B-producing CD8+ T cells from blood 
(D) and brain (F) of PbA-infected mice (day 7) after ex vivo restimulation with GAP-50 peptide. (a–F) *p < 0.05 (two-tailed Student’s t-test). Representative data 
from one of two experiments are shown.
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CD8+ T cells (Figure 10F), were detected in WT mice receiving 
Cyld−/− bone marrow. Strikingly, the reverse transfer, i.e., WT 
bone marrow into Cyld−/− mice, resulted in similar low numbers 
of total and antigen-specific T cells. These results demonstrate 
that the observed lack of ECM symptoms in Cyld−/− mice can be 
attributed to both hematopoietic and parenchymal cells.
DiscUssiOn
This study identifies for the first time a DUB as a crucial host 
factor contributing to the lethal course of ECM. Our detailed 
comparative analysis of P. berghei infection, and the corre-
sponding host immune responses in normal and Cyld−/− mice 
showed that the presence of CYLD impaired parasite control 
and augmented brain pathology by promoting hemorrhage, 
neuroinflammation with activation of astrocytes and micro-
glia, increased accumulation of CD8+ T cells, and apoptosis 
of endothelial cells. During the pre-erythrocytic stage of the 
infection, the parasite liver stages replicate in host hepatocytes 
for 2–3  days before they enter the blood stream. Our study 
shows that upon both sporozoite and blood-stage infection, 
parasitemia was detectable in WT and Cyld−/− mice on day 3 
p.i., indicating that CYLD deficiency did not prevent parasite 
replication in the liver. In this study, we addressed the role of 
CYLD in primary Plasmodium infections and can exclude a 
critical role in pre-erythrocytic parasite development and life 
cycle progression to blood infection, the only parasite stage that 
causes malaria. Future work is warranted to study a potential 
influence of CYLD on the hepatic immune response and 
acquisition of protective immunity after multiple sporozoite 
immunizations.
In marked contrast, the numbers of infected erythrocytes 
were significantly reduced in Cyld−/− mice upon both sporozoite 
or blood-stage PbA-induced infection. This is in contrast to 
our observation in listeriosis (11, 12). Listeria monocytogenes 
(Lm) also replicates in the hepatocytes and additionally in the 
macrophages. We could show previously that CYLD inhibited 
protective hepatocytic and macrophage responses and impaired 
the control of Lm (11, 12).
In both sporozoite and asexual blood stage infections, the 
systemic CD8+ T-cell response was significantly augmented when 
CYLD was absent. Previous studies have consistently shown that 
CD8+ T cells play no role in protection against blood-stage PbA 
infection (41–44). More recent studies have challenged this view 
by showing a major role for parasite-specific CD8+ T cells in 
acute and chronic blood-stage infection (45). In this study, we 
demonstrated a strikingly enhanced CD8+ T cell response follow-
ing acute blood-stage PbA infection in mice that lack the central 
regulator CYLD.
PKC-θ is a key component in the activation of T cells. Our 
previous studies have shown that mice deficient in PKC-θ exhibit 
impaired T cell activation and protection against infectious 
diseases due to reduced activation of NF-κB pathway (46, 47). 
Thuille et al. (38) demonstrated that PKC-θ interacts with CYLD 
leading to inhibition of CYLD function (38). Interestingly, we 
observed increased activation of PKC-θ and NF-κB in CYLD-
deficient CD8+ T cells, suggesting that the interaction between 
CYLD and PKC-θ might also lead to the inhibition of PKC-θ-
mediated NF-κB activation.
Plasmodium berghei ANKA infection was associated with an 
increased expansion of pathogen–specific CD8+ T cells in Cyld−/− 
mice, which in turn was accompanied by augmented production 
of IFN-γ, TNF, granzyme B, and perforin. These cytokines are 
known to contribute to the control of PbA blood parasites. 
Although our CD8+ T cell depletion experiments show the 
importance of CD8+ T cells in the control of PbA blood parasites, 
CD8+ T cell depleted Cyld−/− mice harbored lower parasite loads 
compared to CD8+ T cell-depleted WT mice, indicating that the 
enhanced parasite control in the Cyld−/− mice is also mediated by 
other immune cells in addition to CD8+ T cells.
We have shown before that IFN-γ-stimulated Cyld−/− mac-
rophages have an enhanced capacity to control intracellular 
pathogens (12). Furthermore, it is known that IFN-γ-stimulated 
macrophages exhibit enhanced phagocytosis of parasitized red 
blood cells (48). Our observation of reduced pathogen load in the 
blood of Cyld−/− mice at day 5 p.i., i.e., before the onset of clini-
cal symptoms of ECM, indicates a possible role of macrophages 
in the enhanced clearance of parasitized red blood cells in the 
Cyld−/− mice.
Although CYLD is an important inhibitor of proinflamma-
tory signaling pathways and reduces production of cytokines and 
chemokines, intracerebral cytokine and chemokine production 
of PbA-infected Cyld−/− mice was reduced compared to WT mice. 
Reduced accumulation of pathogen-specific cytokine-producing 
CD8+ T cells could be attributed to reduced expression of the 
chemokine receptor CXCR3 on the Cyld−/− CD8+ T cells, since 
CXCR3 expression on CD8+ T cells is required for T cell migra-
tion into the brain (40) and the development of ECM. Currently, it 
is unclear how CYLD regulates CXCR3 expression, and to clarify 
this aspect, further studies are required. One interpretation of this 
spatial reallocation of CD8+ T cells might be that an increased 
parasite load is a critical factor leading to intracellular cytokine 
and chemokine production and intracerebral accumulation of 
CD8+ T cells. In good agreement with the ameliorated course of 
ECM and the reduced production of intracellular proinflamma-
tory cytokines, brain pathology including blood–brain barrier 
breakdown, perivascular bleeding, activation of astrocytes, and 
microglia were reduced in the Cyld−/− mice.
CD4+ T cells play an important role in controlling blood-
stage malaria (49). Our observation of an enhanced CD4+ T cell 
response in blood of Cyld−/− mice indicates that CYLD also 
impaired CD4+ T cell-mediated protection against PbA infection. 
We also report that the expression of active caspase 3, the effector 
caspase-inducing apoptosis of endothelial cells, was increased in 
Cyld-expressing WT mice. Since Cyld−/− mice are protected from 
apoptosis due to increased NF-κB activation (7), this mechanism 
may also play an important protective role in PbA-infected 
Cyld−/− mice, and future studies on pathogen-induced apoptosis 
of endothelial cells are warranted.
In support of a role of CYLD in parenchymal, and, perhaps, 
endothelial, cells, our bone marrow chimera experiments dem-
onstrate that Cyld expression in radioresistant parenchymal cells 
contributed to the development of lethal ECM. However, com-
plete protection from death was dependent on Cyld deficiency 
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in donor and recipient mice illustrating that CYLD inhibited 
protective host responses both in the immune system and in 
parenchymal cells.
Currently, inhibitors of CYLD and other DUBs are under clini-
cal development, since DUBs are attractive candidate molecules 
in different diseases, including cancer (50). Our data indicate that 
CYLD inhibition might also be an attractive therapeutic option in 
severe malaria in combination with antiparasitic drugs.
MaTerials anD MeThODs
ethics statement
All animal experiments were in compliance with the German 
Animal Welfare Act (TierSchG) in a protocol approved by the 
Landesverwaltungsamt Sachsen-Anhalt (file number: 203.h-
42502-2-901, University of Magdeburg).
animals
Age- and sex-matched animals were used for the experiments. 
C57BL/6 WT were obtained from Janvier (Le Genest Saint Isle, 
France), and C57BL/6 Cyld−/− mice were kindly provided by Dr. 
Ramin Massoumi (Department of Laboratory Medicine, Malmö, 
Sweden) (9). The C57BL/6 Cyld−/− mice were backcrossed with 
C57BL/6 mice for 10 generations. All animals were kept under 
conventional conditions in an isolation facility of the Otto-von-
Guericke University Magdeburg. Experiments were approved 
and supervised by local governmental institutions.
Parasite infection
Plasmodium berghei strain ANKA was used for the experiments. 
For the hepatic stage infection, mice were infected i.v. with 20,000 
live sporozoites obtained from salivary gland homogenate of 
day 21 PbA-infected female Anopheles mosquitoes. For blood-
stage infection, parasites were passaged in C57BL/6J mice, and 
stabilates were harvested and stored in liquid nitrogen (100 µl of 
1 × 106 infected red blood cells in 200 µl Alsever’s solution and 
10% glycerol). For infection, 1 × 106 PbA-infected red blood cells 
were injected i.p., with the dose adjusted for each stabilate batch 
such that neurological signs manifest 7 days later in the major-
ity of mice. The infected mice were monitored for neurological 
symptoms, i.e., paralysis, ataxia, convulsions, and coma occurring 
between day 6 and 10 p.i. (51). Parasitemia was measured daily 
from day 3 p.i. onward by microscopic examination of Giemsa-
stained thin blood smears.
evans Blue staining
Mice were i.v. injected with 100 µl of a 1% solution of Evans blue 
in phosphate-buffered saline (PBS) at day 7 p.i. One hour later, the 
mice were perfused intracardially with 0.9% NaCl after isoflurane 
anesthesia. Brains were removed and photographed.
histopathology
For immunohistochemistry and immunofluorescence on frozen 
sections, mice were perfused intracardially with 0.9% NaCl after 
isoflurane anesthesia. For histology on paraffin sections, anesthe-
tized mice were perfused with 4% paraformaldehyde in PBS and 
brain was removed and fixed with 4% paraformaldehyde for 24 h. 
Paraffin sections (4  µm) were used for hematoxylin and eosin 
staining and immunostaining with antibodies against GFAP and 
Iba1. A total of 7 µm cryostat sections were used for immunostains 
with active caspase-3 and CD31. Immunostaining for these two 
fluorescent markers was performed in staining chambers after 
fixation in acetone and chloroform for 10 and 8 min, respectively. 
The sections were then blocked with appropriate sera (1:10 in 
PBS) dependent on the source of the secondary antibody and 
incubated with the aforementioned primary antibodies at room 
temperature. After washing, the secondary antibody was added for 
1 h. For this double immunostaining, the protocol was performed 
using the first primary antibody, and afterward, the same protocol 
was repeated with the second primary antibody and appropriate 
secondary antibodies. After a final washing step, the sections were 
aqueously mounted and stored at 4°C. Images were acquired with 
an Olympus microscope BX50 and the digital camera DP25 as 
well as cell Sens software (all by Olympus, Hamburg, Germany).
rT-Pcr
Isolation of mRNA from the brains of uninfected and PbA-
infected mice was performed with an RNAeasy kit (Qiagen, 
Hilden, Germany). The SuperScript reverse transcriptase kit with 
oligo (dT) primers (Invitrogen) was used to transcribe mRNA 
into cDNA. Quantitative RT-PCR for IFN-γ, perforin, granzyme 
B, TNF, IL-6, CXCL-9, CXCL-10, LT-α, and hypoxanthine phos-
phoribosyltransferase (HPRT) was performed with cDNA from 
C57BL/6 WT and C57BL/6 Cyld−/− mice and the respective 
Taqman gene expression assay (Applied Biosystems, Darmstadt, 
Germany). Amplification was performed with a GeneAmp 5700 
sequence detection system (Applied Biosystems). Quantitation 
was performed with the sequence detector software SDS (ver-
sion 2.1; Applied Biosystems), according to the ΔΔCT threshold 
cycle method with HPRT as the housekeeping gene (52). Data 
are expressed as the increase in the level of mRNA expression in 
infected mice over that in uninfected controls of the respective 
mouse strain. All primers and probes were obtained from Applied 
Biosystems.
leukocyte isolation
Before isolation of cerebral leukocytes, the animals were 
anesthetized with isoflurane (Baxter, Deerfield, IL, USA) and 
intracardially perfused with 0.9% NaCl to remove contaminat-
ing intravascular leukocytes from the brain. Thereafter, brain 
tissue was minced through a 100-μm pore size cell strainer, and 
leukocytes were separated by Percoll (GE Healthcare, Freiburg, 
Germany) density gradient centrifugation. Peripheral blood was 
obtained by cardiac puncture. The erythrocytes were lysed with 
ammonium chloride, washed twice with ice-cold PBS at 300 × g 
for 10 min, and the leukocyte numbers were counted.
Flow cytometry
Leukocytes isolated from the blood and brain were analyzed by 
flow cytometry on a FACS Canto II with Cell Quest software 
(both from BD Biosciences, Heidelberg, Germany). Cells were 
stained with anti-CD45 in combination with anti-CD8 and anti-
CD3 for CD8+ T cells. All antibodies were obtained from BD 
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Biosciences. For intracellular staining of cytokines, splenocytes 
were stimulated with GAP-50 peptide (SQLLNAKYL, 10  µg/
ml) (36) in RPMI-1640 at 37°C for 4  h according to cytokine 
stimulation protocols by BD. After stimulation, cells were stained 
for CD8+ T cells as described earlier. Thereafter, cells were fixed 
with Cytofix/Cytoperm, permeabilized with Perm Wash (BD 
Biosciences) and stained with intracellular antibodies against 
IFN-γ, TNF, and granzyme B.
generation of Bone Marrow chimera
Bone marrow was collected from WT and Cyld−/− mice. Femur 
and tibia were aseptically removed from mice, the bone ends were 
cut off, and the bone marrow cells were flushed out using PBS 
(4–8°C; Gibco, Darmstadt, Germany). For each chimera, 10 × 106 
cells of bone marrow cells were transferred i.v. into lethally irradi-
ated (one dose of 12 Gy) WT or Cyld−/− recipients. Recipient mice 
were allowed 8  weeks for reconstitution before infection with 
1 × 106 PbA-infected red blood cells.
cytometric Bead array
The serum levels of IL-2, IL-4, IL-6, IL-10, IL-17, IFN-γ, and 
TNF of WT and Cyld−/− mice were analyzed by flow cytometry 
using the Cytometric Bead Array from BD Biosciences using the 
manufacturer’s protocol. Peripheral blood obtained by cardiac 
puncture was centrifuged (490 × g, 5 min) to harvest the serum. 
Cytokine concentration in the serum was determined by add-
ing 50 µl of cytokine-specific capture bead mixture to 50 µl of 
supernatant. Phycoerythrin detection agent (50 µl) was added to 
each sample and incubated in the dark at 4°C for 2 h. Thereafter, 
the samples were supplemented with 1  ml washing buffer and 
centrifuged at 200 × g for 5 min. The supernatant was discarded, 
and the cell pellet was resuspended in washing buffer (300 µl). 
The cytokine levels were measured using a FACS Canto II (BD 
Biosciences) and analyzed with FCAP Array™ software (version 
3, BD Biosciences).
cD8+ T cell Depletion
CD8+ T cells were depleted by the injection of rat anti-mouse CD8 
β (clone 53.5.8) (BioXell, West lebanon, NH, USA). Depletion 
was performed by i.p. injection of 500 µg of purified anti-CD8+ 
T  cell antibody starting 3  days before infection. Control mice 
were treated with i.p. injection of 500 µg of non-immune rat IgG. 
The depletion was assessed by flow cytometry.
statistics
Statistical differences for survival curves were analyzed by log-rank 
test. Statistical differences between groups were analyzed using 
the two-tailed Student’s t-test. All experiments were performed at 
least twice. P values of <0.05 were considered significant.
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FigUre s1 | increased levels of interferon (iFn)-γ in the serum of 
Cyld−/− mice. The serum concentrations of interleukin (IL)-10, IL-17, tumor 
necrosis factor, IFN-γ, IL-6, IL-4, and IL-2 were determined in Plasmodium 
berghei ANKA (PbA)-infected WT (open symbols) and Cyld−/− mice (black 
symbols) by a cytometric bead assay at day 7 postinfection. IFN-γ levels were 
significantly increased in Cyld−/− mice compared to WT mice. *p < 0.05 
(two-tailed Student’s t-test). Six mice were analyzed per group, and 
representative data are shown.
FigUre s2 | enhanced Plasmodium berghei anKa (Pba)-specific cD8+ 
T cell response in the blood of Cyld−/− mice after blood stage infection. 
(a) Relative numbers of PbA antigen-specific granzyme B-producing CD8+ 
T cells from uninfected (day 0) and PbA-infected WT and Cyld−/− mice (day 7). 
(B) Absolute numbers of CD3+CD8+ T cells in the blood of uninfected (day 0) and 
PbA-infected WT and Cyld−/− mice (day 7) (n = 6 each). (c) Absolute number of 
interferon-γ-producing CD8+ T cells in the blood of uninfected (day 0) and 
PbA-infected mice (day 7) after ex vivo restimulation with GAP-50 peptide. 
*p < 0.05 (two-tailed Student’s t-test). Data from one of three independent 
experiments are shown.
FigUre s3 | reduced Plasmodium berghei anKa (Pba)-specific cD8+ 
T cell response in the brain of Cyld−/− mice after blood-stage infection. 
(a,B) Absolute numbers of CD3+ CD8+ T cells (a) and interferon-γ-producing 
CD8+ T cells (B) after ex vivo restimulation with GAP-50 peptide in the brains of 
uninfected (day 0) and PbA blood stage-infected mice (day 7) in WT and 
Cyld−/− mice (n = 6 each). *p < 0.05 (two-tailed Student’s t-test). Data from one 
of three independent experiments are shown.
FigUre s4 | efficient depletion of cD8+ T cell by monoclonal antibody 
treatment. C57BL/6 Cyld−/− and WT (n = 6) mice were either treated with 
anti-CD8 antibody or rat IgG starting 3 days before intraperitoneal infection with 
1 × 106 Plasmodium berghei ANKA-infected red blood cells. At day 7 
postinfection, efficiency of T cell depletion was determined by flow cytometry. 
Data show relative numbers of anti-CD3- and anti-CD8-stained blood cells of 
representative mice (n = 3 per group).
FigUre s5 | reduced chemokine receptor expression by cD8+ T cell in 
the spleen of Cyld−/− mice after blood-stage infection. (a,c) Histogram 
overlays show data for CCR1 (a) and CCR5 (c) expression in CD3+ CD8+ T cells 
of uninfected (day 0) and day 7 postinfection (day 7) WT and Cyld−/− mice. (B,D) 
The mean fluorescence intensity of CCR1 (B) and CCR5 (D) is shown for WT 
and Cyld−/− mice at the indicated time points. Specific staining for WT mice is 
shown in light gray and for Cyld−/− mice in dark gray. Data from one of two 
experiments (n = 6) are shown.
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